Article Text

Download PDFPDF
Withdrawal of ‘Xigris’ from the market: old and new lessons

Statistics from


  • Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests DP has no conflict of interest. GB was a member of the European Medicines Agency (EMEA) Ad Hoc Expert Group for the second annual reassessment of DrotAA. SG was a member of the EMEA Committee for Medicinal Products for Human Use (CHMP) from 1997 to 2004.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.